Atovaquone: an inhibitor of oxidative phosphorylation as studied in gynecologic cancers

HIGHLIGHTS

  • who: Arvinder Kapur and colleagues from the Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, USA have published the research: Atovaquone: An Inhibitor of Oxidative Phosphorylation as Studied in Gynecologic Cancers, in the Journal: (JOURNAL)
  • what: The studies provide the mechanistic understanding 4.0/). __NEWPAGE__Cancers 2022 14 2297 2 of 17 and preclinical data to support the further investigation of atovaquone's potential as a cancer therapeutic. The authors demonstrate the anti-cancer activity of atovaquone in ovarian and endometrial cancers and confirm its mechanism of action through comprehensive molecular and cellular . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?